MedAvante’s proven clinical expertise ensures our platform and services are the most reliable solutions for signal detection. Our continuing clinical innovations enable us to facilitate smarter, faster clinical trials.
In 2002 MedAvante set out to solve one of Pharma’s most intractable problems: the bias and variability that cause failed or inconclusive trials for Central Nervous System (CNS) therapies.
In 2005 we pioneered Central Ratings to standardize outcome assessments, thereby reducing bias and variability and significantly increasing signal detection.
In 2009 we introduced Central Review and our groundbreaking Virgil eSource solution. Virgil leverages our in-house rater network and expertise to provide integral clinical guidance to raters.
MedAvante has a history of proven innovation – first with Central Ratings and Review, and now with our best-in-class eSource platform.
Today: our study platform Virgil and our suite of clinical services continue to improve signal detection and prevent inconclusive trial results.
Virgil provides sites, sponsors and CROs with the tools, data-driven insights and guidance they need to operate more easily and efficiently.
Virgil has been shown to reduce error by at least 80% compared to paper.
Virgil captures and secures the highest-quality study data to help sponsors achieve more conclusive clinical trials.
Virgil was created by clinicians, for clinicians. Virgil addresses the real needs of raters and coordinators, and reduces process complexity and administrative burden for sites.
Virgil enables eSource assessments including:
• Clinician Reported Outcomes (eClinRO)
• Observer-Reported Outcomes (eObsRO)
• Patient Reported Outcomes (ePRO)
Virgil is reliable. MedAvante has not lost a single data element in more than eight years of use and over three and a half million pages of data.
Virgil amplifies the power of MedAvante’s key risk-reduction services by digitally delivering Central Ratings and Review. It eliminates paper through direct data capture, and increases sponsors’ strategic options by enabling smart trials with real-time analytics.
“Losing patient data can be tragic. I look very carefully at data loss rates because I want them to be 0.01% or 0%. I cannot afford to lose data. The loss rates are a way that I differentiate one provider from another.”
“The industry is hungry for innovation. And they’re hungry for innovation because the current models are struggling.”
We provide clinicians and researchers with the tools, data-driven insights, and guidance they need to get their work done more easily and efficiently.
Our services, technologies, and clinical guidance help bring drug therapies to market with smarter, faster, more adaptive clinical trials.